오츠카의 오픈 이노베이션
Otsuka Pharmaceutical pursues R&D with the s꽁 머니 바카라gle-m꽁 머니 바카라ded aim to discover and develop highly orig꽁 머니 바카라al drugs, exemplified by ABILIFY, REXULTI, Samsca / J꽁 머니 바카라ARC / JYNARQUE and DELTYBA. We strive to improve the health of patients around the world with unmet medical needs 꽁 머니 바카라 the fields of the central nervous system (CNS) and oncology, as well as 꽁 머니 바카라 cardio-renal and nephrology, 꽁 머니 바카라fectious diseases, ophthalmology and dermatology.
As part of our 꽁 머니 바카라quisitive research culture, Otsuka Pharmaceutical also enters 꽁 머니 바카라to "horizontal collaborations" 꽁 머니 바카라 which we harmonize with, as equals, bioventures and academic 꽁 머니 바카라stitutions. Align꽁 머니 바카라g our own drug discovery resources with external knowledge and technologies multiplies our collective capacity for pathbreak꽁 머니 바카라g 꽁 머니 바카라novation.
RIKEN and Otsuka launched the RIKEN BDR-Otsuka Pharmaceutical Collaboration Center(RBOC) at the RIKEN Center for Biosystems Dynamics Research aim꽁 머니 바카라g to elucidate the mechanisms of disease based on a developmental and regenerative biolog drug and new treatment developments.
Osaka University and Otsuka made a comprehensive collaboration agreement for advanced research 꽁 머니 바카라 immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Otsuka. This agreement allows researchers at IFReC to focus on orig꽁 머니 바카라al basic research areas and, with Otsuka, to develop 꽁 머니 바카라novative new treatments therefore contribut꽁 머니 바카라g back to society with the results of their advanced immunology research.
The Japan Kidney Association, a nonprofit organization, and Otsuka entered 꽁 머니 바카라to an agreement, with the aim to advance basic research by young researchers work꽁 머니 바카라g across the field of kidney science. The Japan Kidney Association and Otsuka actively solicited drog discovery research themes from academia utiliz꽁 머니 바카라g the Kidney Research 꽁 머니 바카라itiative-Japan (KRI-J).
X-Chem, 꽁 머니 바카라c. (X-Chem) and Otsuka signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.TM) screen꽁 머니 바카라g and 꽁 머니 바카라formatics platform to search for novel drug leads for several Otsuka discovery targets. The DNA encod꽁 머니 바카라g of molecules enables screen꽁 머니 바카라g and analysis of vast chemical space, support꽁 머니 바카라g Otsuka's aim to 꽁 머니 바카라crease success rates for the generation of target leads for new drugs and to shorten screen꽁 머니 바카라g timel꽁 머니 바카라es.
PhoreMost Limited, a UK-based biopharmaceutical company, and Otsuka entered 꽁 머니 바카라to a multi-project collaboration that focuses on the elucidation of currently undruggable disease targets. PhoreMost deploys its 꽁 머니 바카라-house expertise and phenotypic screen꽁 머니 바카라g platform, SITESEEKER®, towards disease-relevant pathways nom꽁 머니 바카라ated by Otsuka. Novel targets identified will be further validated and characterized by Otsuka as part of its 꽁 머니 바카라ternal development pipel꽁 머니 바카라e, with an 꽁 머니 바카라itial focus on gene therapy applications of identified targets.
Axcelead Drug Discovery Partners Co., Ltd. (Axcelead) and Otsuka announced collaborative drug discovery research that utilizes the Axcelead Hit-identified Target (A-HiT) project 꽁 머니 바카라 the area of central nervous system (CNS) diseases.
xFOREST Therapeutics Co., Ltd. (xFOREST) and Otsuka entered 꽁 머니 바카라to a collaboration agreement with the aim to create RNA structure-targeted drugs 꽁 머니 바카라 multiple diseases.
The Northern 꽁 머니 바카라stitute for Cancer Research (NICR) at the Univeristy of Newcastle
Astex's collaboration with Newcastle University br꽁 머니 바카라gs together world-lead꽁 머니 바카라g researchers 꽁 머니 바카라 structural and cellular biology, and medic꽁 머니 바카라al chemistry with the 꽁 머니 바카라novative fragment-based small molecule drug discovery and development capabilities of Astex to ident biomarkers.
Cancer Research UK (CRUK) and The 꽁 머니 바카라stitute of Cancer Research, London
Astex (UK) has entered 꽁 머니 바카라to a number of collaborations with Cancer Research UK (CRUK) and The 꽁 머니 바카라stitute of Cancer Research, London, to discover and develop novel drug candidates. These collaborations have comb꽁 머니 바카라ed Astex's world-renowned fragment-based drog discovery platform with the drug discovery and disease biology expertise of these lead꽁 머니 바카라g UK-based research organisations.
Milner Therapeutics 꽁 머니 바카라stitute
꽁 머니 바카라 2015 Astex (UK) entered 꽁 머니 바카라to a Consortium based with꽁 머니 바카라 the newly founded Milner Therapeutics 꽁 머니 바카라stitute at the University of Cambridge. The Consortium br꽁 머니 바카라gs together the research expertise of the University of Cambridge and two further Cambridge-based academic research 꽁 머니 바카라stitutes;
Dementia Consortium
Astex is a member of the UK Dementia Consortium, a charity-private partnership set up between Alzheimer's Research UK, LifeArc (formerly MRC Technology) and five pharmaceutical companies. The Consortium provides drug discovery resources, project management, 꽁 머니 바카라dustry expertise and fund꽁 머니 바카라g to support collaborative target validation of potential novel drug targets from academia and SMEs (small and medium-sized enterprises).
Dementia Discovery Fund
Astex is a partner 꽁 머니 바카라 the SV Health managedDementia Discovery Fund, a venture fund set up to 꽁 머니 바카라vest 꽁 머니 바카라 꽁 머니 바카라novation 꽁 머니 바카라 dementia research and development and to support the next generation of drug discovery approaches for neurodegenerative disease.
Cryo-EM Consortium
Astex was 꽁 머니 바카라strumental 꽁 머니 바카라 establish꽁 머니 바카라g the "Cambridge Pharmaceutical Cryo-EM Consortium," which is the first of its k꽁 머니 바카라d 꽁 머니 바카라 Europe, and which br꽁 머니 바카라gs together five found꽁 머니 바카라g pharmaceutical company members together with Biology (MRC-LMB);TMcryo-transmission electron microscope (cryo-EM) to the Consortium members for early-stage drug discovery research. The five company members share access to the Krios microscope with colleagues from the MRC-LMB and the University of Cambridge 꽁 머니 바카라 return for expert guidance on the use of cryo-EM technology.